Azitra halts at-the-market share sales after selling 1,000 shares for about $126
Azitra said it will not sell shares under its at-the-market offering program with A.G.P./Alliance Global Partners for the foreseeable future. From September 28 through October 26, 2026, the company sold 1,000 shares for approximately $126 in gross proceeds, and it may resume sales or pursue other financing at any time. The same day, it released ex vivo study results for its ATR-COSF cosmetic candidate and said first-in-human initial results are expected by year end.
Key points
- From September 28 through October 26, 2026, Azitra sold 1,000 shares under the ATM Program for aggregate gross proceeds of approximately $126.
- On October 26, 2026, the company decided not to use the ATM Program for the foreseeable future, citing capital resources, upcoming operational milestones, the recent trading price and dilution to existing stockholders.
- The company may resume ATM sales or pursue other financing transactions at any time and gave no assurance as to whether or when it will do so.
- The same-day press release reported ex vivo data for ATR-COSF; detailed data are to be presented at BIO-Europe in Cologne on November 10, 2026, and first-in-human initial data are expected by year end.
The filing
Written by AI on Nov 9, 2026, 8:53 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on October 26, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.